Conference Reports for NATAP

Back

Conference on Retroviruses and Opportunistic Infections WASHINGTON STATE CONVENTION CENTER Seattle, Washington March 4-7, 2019     Cardiovascular Update from CROI 2019 - by Priscilla Hsue MD Professor of Medicine, UCSF - (07/01/19)   Bone, Frailty, and Aging at CROI 2019 - Todd Brown, MD, PhD Division of Endocrinology, Diabetes, & Metabolism Johns Hopkins University - (05/31/19)   Complicated Complications at CROI - David Alain Wohl, MD - The University of North Carolina Institute of Global Health and Infectious Diseases - (04/26/19)   Summary from CROI 2019 for viral Hepatitis Curing viral hepatitis: what are the clinical implications and what are the remaining barriers to overcome? - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany (04/08/19)   HIV Prevention at CROI 2019 - Jared Baeten, MD PhD Connie Celum, MD MPH University of Washington - (03/29/19)   26th Conference on Retroviruses and Opportunistic Infections (CROI) March 4-7, 2019 Seattle, WA - Eric S. Daar, M.D. - (03/29/19)   Clinical Pharmacology at CROI 2019 - Courtney V. Fletcher, Pharm.D. Professor UNMC Center for Drug Discovery University of Nebraska Medical Center 986000 Nebraska Medical Center Omaha, NE 68198 (04/09/19)   ---------------------------------------------------------- Longitudinal Phenotyping of Declarative Memory Among Women Living with HIV - (01/24/20)   CEREBRAL FUNCTION PARAMETERS IN PEOPLE LIVING WITH HIV SWITCHING INTEGRASE INHIBITOR - (08/02/19)   TOCILIZUMAB (monoclonal antibody) ALTERS LIPIDS IN HIV+ INDIVIDUALS IN A RANDOMIZED, DOUBLE-BLIND STUDY - (07/10/19)   Lower bone strength by peripheral quantitative CT (pQCT) in children living with HIV - (06/05/19)   HIV Infection and the Risk of Fracture among Fallers - (05/31/19)   Senescence & Exhaustion of T Cell Memory Subsets Increased in Aging Persons with HIV - (05/31/19)   Mood Disorders & Increased Risk of Non-communicable Diseases in Adults Aging with HIV.....more HIV+ females had mood disorders 27% vs 22% - (05/31/19)   MECHANISMS OF WHITE-MATTER LOSS DUE TO HIV INFECTION AND ANTIRETROVIRAL THERAPY - (05/13/19)   RELAPSE OF SYMPTOMATIC CSF HIV ESCAPE UPON PREVIOUSLY OPTIMIZED cART REGIMEN CHANGES / CNS Eradication Reservoir - (05/13/19)   HIV is Associated with Lung Function Impairment in the Multicenter AIDS Cohort Study - (04/28/19)   2 Studies on Sudden Cardiac Death in HIV+ at CROI 2019 with surprising findings regarding causes of deaths - (04/28/19)   Updates New ARTs/ New ART Data - CROI including Bictegravir, Dolutegravir+Rilpivirine, Dolutegravir+3TC, Doravirine; Fostemsavir & MK-8591 - (04/10/19)   CAN'T BUY ME LOVE? OBSTACLES TO MICRO-ELIMINATION OF ACUTE HCV COINFECTION IN EUROPE - (04/08/19)   GS-6207, A POTENT AND SELECTIVE FIRST-IN-CLASS LONG-ACTING HIV-1 CAPSID INHIBITOR - (04/08/19)   Weight Gain in HIV - Integrase - (04/08/19)   HIGH RATES OF VIROLOGIC SUPPRESSION AFTER RAPID ART START IN A SAFETY-NET CLINIC - (04/05/19)   Aging At CROI 2019 - (04/02/19)   EFFECT ON PLASMA NFL, A MARKER OF NEURONAL INJURY, AFTER SWITCHING FROM TDF TO TAF - (04/01/19)   EFFECTS OF PROBIOTIC VISBIOME ES ON COLONIC MUCOSAL CD4 CELLS: RESULTS FROM A5352S - (04/01/19)   BENEFICIAL EFFECT OF 6 MONTHS OF PROBIOTICS ON ASYMPTOMATIC NEUROCOGNITIVE IMPAIRMENT - (04/01/19)   Changes in Kidney Function Among MSM Initiating On-Demand TDF/FTC for HIV Pre-Exposure Prophylaxis - (03/29/19)   I Keep Forgetting HIV, Aging, and Cognitive Disorders - (03/29/19)   THE PROJECTED AGE DISTRIBUTION OF WHITE, BLACK, AND HISPANIC MSM ON ART, 2009-2030 / 20% White MSM Projected to be over 70 by 2030 - (03/28/19)   THE PROJECTED AGE DISTRIBUTION OF WHITE, BLACK, AND HISPANIC MSM ON ART, 2009-2030 - (03/28/19)   Earlier Age of Onset and Higher Prevalence of Comorbidities in People Living with HIV: A Population-Based Cohort Study in British Columbia, Canada - (03/28/19)   PROJECTED GROWTH AND NEEDS OF AGING PLWH IN HRSA'S RYAN WHITE HIV/AIDS PROGRAM .....from 2010 through 2030 % > 50 years old doubles with curve sharply increasing-see graph below - (03/28/19)   Hepatitis at CROI 2019: HCV, NASH, HBV; HIV+ MSM Reinfection in NYC; New HCV Cases Sharp Drop in London - (03/27/19)   Suicide rates among adults living with HIV, 2000-2015 - (03/28/19)   Delayed HCC Diagnosis in HIV/HCV Coinfected: HIV not linked to worse liver cancer survival in people with HCV - (03/26/19)   AIDS illness, living in US South, lower CD4s linked to longer hospital stay with HIV - (03/26/19)   Factors associated with therapeutic failure of 2-drug regimens, DAT'AIDS cohort: Two-antiretroviral maintenance failure--raltegravir regimens seem most vulnerable - Mark Mascolini (03/26/19)   Integrase Strand Transfer Inhibitors are Associated With Weight Gain in Women - (03/25/19)   Can HBV Be Cured? - "Single hepatocyte analysis in HIV-HBV co-infection shows transcriptional silencing" - (03/22/19)   Real-life efficacy and safety of Glecaprevir/Pibrentasvir in a large cohort of HCV-infected patients: the MISTRAL study - (03/20/19)   Liver stiffness at SVR predicts hepatic complications in HCV-infected patients - (03/20/19)   Integrase Inhibitor Exposure and Central Nervous System & Neural Tube Defects - Data from the Antiretroviral Pregnancy Registry - (03/20/19)   Inflammation, Arterial Stiffness and Directly-Acting Antivirals in HCV and HIV/HCV, no beneft observed in this study - (03/20/19)   Successful HCV treatment does not affect rate of heart disease or non-AIDS cancer - Mark Mascolini (03/20/19)   DAA therapy for HCV lowers risk of cardiovascular disease at all fibrosis stages - (03/20/19)   Maternal HBV Viremia Is Associated With Adverse Infant Outcomes In HIV/HBV Women: Post-Hoc Analysis of HPTN 046 - (03/20/19)   HCV treatment with DAAs halves risk of new diabetes diagnosis - Mark Mascolini (03/20/19)   High maternal HBV with HIV tied to low infant weight and HIV transmission - Mark Mascolini (03/20/19)   High endothelial dysfunction rate with recent HIV in young adults with low cardiovascular risk - Mark Mascolini (03/19/19)   ART IN EARLY INFECTION IMPROVES NEUROCOGNITION REGARDLESS OF INFECTION DURATION - (03/19/19)   GENOTYPIC AND PHENOTYPIC SUSCEPTIBILITY TO FOSTEMSAVIR IN MULTIDRUG-RESISTANT HIV-1 - (03/19/19)   DOLUTEGRAVIR: ABSENCE OF DEVELOPMENTAL TOXICITY INCLUDING NTDs IN ANIMAL STUDIES - (03/19/19)   NO INCREASE IN BIRTH DEFECTS IN INFANTS EXPOSED TO INTEGRASE INHIBITORS AT CONCEPTION - (03/19/19)   Integrase Inhibitor Exposure and CNS and Neural Tube Defects: Data from the Antiretroviral Pregnancy Registry (APR) - (03/19/19)   Reports of Neural Tube Defects for 8 ARVs in FDA, WHO, EMA and UK Pharmacovigilance Safety Databases - (03/19/19)   Antiretroviral Adherence and HIV-1 Drug Resistance in the US - (03/19/19)   RELAPSE OF SYMPTOMATIC CSF HIV ESCAPE UPON PREVIOUSLY OPTIMIZED C-ART REGIMEN CHANGES - (03/18/19)   Combination of CRISPR and LASER ART Eliminates Replication Competent Rebound in Humanized Mice - (03/18/19)   Lymphoid Tissue Pharmacokinetics of Tenofovir-alafenamide vs. disoproxil fumarate - (03/18/19)   MODERATE EFFICACY OF ORAL SINGLE-AGENT TAF AGAINST VAGINAL SHIV INFECTION IN MACAQUES - (03/18/19)   USING EHR DATA TO IDENTIFY POTENTIAL PREP CANDIDATES IN A LARGE HEALTH CARE SYSTEM - (03/18/19)   Prediction of Renal OAT1 and OAT3 Inhibition by Cabotegravir Using PBPK Modelling - (03/18/19)   Hormonal Contraceptives Do Not Alter Cabotegravir PK in HIV Uninfected Women: HPTN 077 - (03/18/19)   Immediate PrEP Initiation at New York City Sexual Health Clinics - (03/18/19)   One in 50 in NYC with recently diagnosed HIV used PrEP in preceding months..... PrEP Use in Persons With Undetected HIV Infections Contributes to Resistance - Mark Mascolini (03/18/19)   Sex-specific Patterns in HIV-associated Cardiovascular Mortality in New York City - (03/18/19)   New HIV/ART Drugs at CROI 2019 - (03/18/19)   THERAPEUTIC ACTIVITY OF PGT121 MONOCLONAL ANTIBODY IN HIV-INFECTED ADULTS - (03/18/19)   GS-9722: First-in-Class, Effector-Enhanced, Broadly Neutralizing Antibody for HIV Cure - and PGT121 in HIV+ / PGT121 bNAb in HIV+ - (03/15/19)   CHARACTERIZING THE HIV DNA RESERVOIRS IN WHOLE-BODY TISSUES IN THE "LAST GIFT" COHORT - (03/15/19)   A Phase IIa Study of a Novel Maturation Inhibitor GSK2838232 in HIV patients - (03/15/19)   Susceptibility to Bictegravir in Highly ARV Experienced Patients After INSTI Failure - (03/15/19)   Long-Term B/F/TAF Switch Efficacy in Patients with Archived Pre-Existing Resistance - (04/08/19)   High Level of Preexisting NRTI Resistance Prior to Switching to B/F/TAF: Study 4030 - (03/15/19)   Sharp drop in acute HCV among London MSM with HIV after DAAs arrived - Mark Mascolini (03/15/19)   BICTEGRAVIR/FTC/TAF SINGLE-TABLET REGIMEN IN ADOLESCENTS & CHILDREN: WEEK 48 RESULTS - (03/15/19)   Half with HIV in US have virus over 3 years before diagnosis--some groups lag overall trends - "Duration of infectiousness among persons with HIV diagnosed during 2012-2016" - Mark Mascolini (03/15/19)   Frequent PSA screening, lower prostate cancer incidence, in veterans with HIV - Mark Mascolini (03/15/19)   In utero HIV exposure tied to obesity, reactive airway disease in adolescence - Mark Mascolini (03/15/19)   HIV Resistance Associated Mutations Observed in Cell-Associated DNA Sequencing Assay - (03/14/19)   Oral TAF alone offers modest protection against vaginal SHIV in monkeys - Mark Mascolini (03/14/19)   New fracture independently boosts death risk in big US HIV cohort - Mark Mascolini (03/14/19)   BICTEGRAVIR CONCENTRATIONS AND VIRAL SUPPRESSION IN CSF of HIV-INFECTED PATIENTS - (03/14/19)   PRO 140 (leronlimab) SC: Long-Acting Single-Agent Maintenance Therapy (SAMT) for HIV-1 Infection - (03/14/19)   FAVOURABLE OUTCOME of IN VITRO SELECTIONS WITH NOVEL NRTI PRODRUG GS-9131 - (03/14/19)   PML-IRIS ensuing CNS and subsequent peripheral viral escape of ARV-resistant variants - (03/14/19)   Rebound Of HIV-1 In Cerebrospinal Fluid (CSF) After Treatment Interruption (TI) - (03/14/19)   Changes in HIV PrEP awareness and use among men who have sex with men, 2014 vs 2017 - (03/14/19)   Neurosymptomatic HIV-1 CSF Escape can Occur with Replication in CD4+ T Cells in the CNS - (03/13/19)   Estimated PrEP Eligibility in a National Sexual Network Study of US MSM - (03/13/19)   Neurosymptomatic HIV-1 CSF Escape can Occur with Replication in CD4+ T Cells in the CNS - (03/13/19)   Up to 95% virologic response rate with rapid ART in safety-net clinic - Mark Mascolini (03/13/19)   Estimate of US MSM eligible for PrEP jumps from 25% in 2015 to 45% today - Mark Mascolini (03/13/19)   TENOFOVIR ALAFENAMIDE VS TENOFOVIR DF IN WOMEN: POOLED ANALYSIS OF 7 CLINICAL TRIALS - (03/13/19)   DIFFERENTIAL BMI CHANGES FOLLOWING PI- AND INSTI- BASED ART INITIATION BY SEX AND RACE - (03/13/19)   Viral Suppression Among People Initiating HIV Care: Outcomes from iENGAGE Trial - (03/13/19)   Injecting drugs, HCV, race are syphilis risk factors in US women with HIV - Mark Mascolini (03/13/19)   More than 1 year to HIV control raises failure risk almost 10-fold - Mark Mascolini (03/13/19)   Single monoclonal antibody infusion controls HIV for over 5 months in 2 people - - Mark Mascolini (03/13/19)   ACTIVITY OF ECD4-IG AGAINST CCR5 ANTAGONIST-RESISTANT HIV-1 - (03/13/19)   IBALIZUMAB: 96-WEEK DATA AND EFFICACY IN PATIENTS RESISTANT TO COMMON ANTIRETROVIRALS - (03/13/19)   Rebound of HIV-1 in Cerebrospinal Fluid (CSF) after Treatment Interruption (TI). Themed discussion webcast - (03/13/19)   DTG vs LPV/r (DAWNING): Efficacy by Baseline NRTI Resistance and Second-Line NRTI Use - (03/13/19)   Efficacy and Safety of the Once-daily Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Single-tablet Regimen in Antiretroviral Treatment (ART)-experienced and ART-naïve Women Living with HIV-1: EMERALD and AMBER Week 96 Results - (03/13/19)   Efficacy and Safety of the Once-daily Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Single-tablet Regimen in Antiretroviral Treatment (ART)-experienced and ART-naïve Women Living with HIV-1: EMERALD and AMBER Week 96 Results - (03/13/19)   RETREATMENT OF HCV IN ADVANCED LIVER DISEASE / CROI 2019 - (03/12/19)   A PHASE ONE STUDY OF LEDIPASVIR/SOFOSBUVIR IN PREGNANT WOMEN WITH HEPATITIS C VIRUS - (03/12/19)   Primary HCV in HIV+ MSM: US Epidemic Incidence - (03/12/19)   Fall in HCV incidence in HIV+ MSM in London following expansion of access to DAA therapy - (03/12/19)   Successful HCV treatment does not affect rate of heart disease or non-AIDS cancer - Mark Mascolini (03/12/19)   LONG-ACTING CABOTEGRAVIR + RILPIVIRINE FOR HIV MAINTENANCE: FLAIR WEEK 48 RESULTS - (03/11/19)   Obesity & Weight Gain on Antiretroviral Therapy - (03/11/19)   RISK FACTORS FOR EXCESS WEIGHT GAIN FOLLOWING SWITCH TO INTEGRASE INHIBITOR-BASED ART - (03/11/19)   Dolutegravir and Insulin Resistance - (03/11/19)   MIDLIFE ADIPOSITY PREDICTS COGNITIVE DECLINE IN THE MULTICENTER AIDS COHORT STUDY (MACS) - (03/11/19)   Pharmacogenetics of Weight Gain after Switch from Efavirenz to Integrase Inhibitors - (03/11/19)   LONG-LASTING ALTERATIONS IN FAT DISTRIBUTION IN PLWH EXPOSED TO THYMIDINE ANALOGUES - (03/11/19)   Weight Gain During Treatment Among 3,468 Treatment-Experienced Adults with HIV - (03/11/19)   GREATER WEIGHT GAIN AMONG TREATMENT-NAIVE PERSONS STARTING INTEGRASE INHIBITORS - (03/11/19)   Weight Gain among Virally Suppressed Persons who Switch to INSTI-Based ART, The HIV Outpatient Study - (03/11/19)   Two thirds of HIV group report pain and 14% endure "widespread" pain [50% to 80% report pain, average age only 53] - Mark Mascolini (03/11/19)   The Impact of Weight Gain and Sex on Immune Activation Following Initiation of ART - (03/11/19)   INTEGRASE STRAND TRANSFER INHIBITORS ARE ASSOCIATED WITH WEIGHT GAIN IN WOMEN - (03/11/19)   Higher cardiovascular risk in older HIV group tied to worse cognitive function - Mark Mascolini (03/08/19)   One in 50 in NYC with recently diagnosed HIV used PrEP in preceding months - Mark Mascolini (03/08/19)   One third of elderly HIV group takes complex regimens and risks drug interactions - Mark Mascolini (03/08/19)   HIV-Cognitive Impairment/Obesity-Overweight-Exercise-Efavirenz-Age "OBESITY IS INDEPENDENTLY ASSOCIATED WITH NEUROCOGNITIVE DECLINE IN HIV".....16% had neurocognitive impairment (NCI) & 6% frailty at baseline (03/08/19)   Changes in Lipids After a Direct Switch from TDF to TAF (03/08/19)   Memory and Learning Dysfunction with Integrase Strand Transfer Inhibitor Use (03/08/19)   MK-8591 Potency and PK Provide High Inhibitory Quotients at Low Doses QD and QW (03/08/19)   Once-Daily Doravirine in HIV-1-Infected, Antiretroviral-Naive Adults: An Integrated Efficacy Analysis (03/08/19)   Obesity--but not frailty--predicts neurocognitive impairment with HIV - Mark Mascolini (03/08/19)   SAFETY AND PK OF SUBCUTANEOUS GS-6207, A NOVEL HIV-1 CAPSID INHIBITOR (03/08/19)   Efficacy of the Two-Drug Regimen of Dolutegravir Plus Lamivudine (DTG+3TC) vs Dolutegravir Plus Tenofovir/Emtricitabine (DTG+TDF/FTC) at W48 in Antiretroviral Naive Women: GEMINI Studies Subgroup Analysis (03/08/19)   Week 48 Safety and Efficacy of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Heavily Treatment-Experienced Women in the BRIGHTE Study (03/08/19)   ViiV Healthcare Presents Positive, 48-Week Data from Two Pivotal Phase III Studies Showing Long-Acting, Injectable Two-Drug Regimen of Cabotegravir and Rilpivirine Has Similar Efficacy to Daily, Three-Drug Oral Treatment in Adults Living with HIV-1 Infection (03/08/19)   Monthly injected cabotegravir/rilpivirine noninferior to oral DTG at 48 weeks - Mark Mascolini (03/08/19)   Janssen Announces Results Of Two Phase 3 Studies Which Showed Long-Acting Injectable HIV Treatment Regimen Of Rilpivirine And Cabotegravir Demonstrated Comparable Safety And Efficacy To Daily Oral HIV Therapy (03/08/19)   ANALYTIC TREATMENT INTERRUPTION (ATI) AFTER ALLOGENEIC CCR5-D32 HSCT FOR AML IN 2013 (03/08/19)   Lymphoid Tissue Pharmacokinetics of Tenofovir-alafenamide vs. disoproxil fumarate (03/08/19)   Lymphoid tissue PKs of tenofovir-alafenamide vs. -disoproxil fumarate / Tenofovir levels in human PBMCs and lymph nodes higher with TAF than TDF - Mark Mascolini (03/08/19)   Yearly suicide rate in white men with HIV usually far exceeds rate in US population - Mark Mascolini (03/08/19)   LONG-ACTING CABOTEGRAVIR + RILPIVIRINE FOR MAINTENANCE THERAPY: ATLAS WEEK 48 RESULTS (03/07/19)   SUSTAINED HIV-1 REMISSION FOLLOWING HOMOZYGOUS CCR5 DELTA32 ALLOGENIC HSCT (03/07/19)   Edoxaban lowers coagulation but not inflammation in people on ART - Mark Mascolini (03/07/19)   Cognitive impairment tied to doubled death risk in US and African HIV groups - Mark Mascolini (03/07/19)   Higher risk of recurrent venous thromboembolism with HIV in Dutch national study - Mark Mascolini (03/07/19)   Successful HCV treatment does not affect rate of heart disease or non-AIDS cancer - Mark Mascolini (03/07/19)   Clinical Outcomes in Persons Coinfected with HIV and HCV: Impact of HCV Treatment - (03/07/19)   INCIDENT DIABETES AND GLUCOSE CONTROL AFTER HCV TREATMENT WITH DAAS IN ERCHIVES - (03/07/19)   Effects of eradication of HCV on bone mineral density in HIV/HCV-coinfected patients - Bone density stable over 96 weeks after DAA cure in HIV/HCV group - Mark Mascolini - (03/07/19)   Clinical Outcomes in Persons Coinfected with HIV and HCV: Impact of HCV Treatment - Mark Mascolini - (03/07/19)   Higher HIV load, lower CD4s predict liver cancer without advanced fibrosis - Mark Mascolini - (03/07/19)   THE PHASE 3 DISCOVER STUDY: DAILY F/TAF OR F/TDF FOR HIV PREEXPOSURE PROPHYLAXIS - (03/06/19)   EFFECTS OF PROBIOTIC VISBIOME ES ON COLONIC MUCOSAL CD4 CELLS: RESULTS FROM A5352S - (03/06/19)   BENEFICIAL EFFECT OF 6 MONTHS OF PROBIOTICS ON ASYMPTOMATIC NEUROCOGNITIVE IMPAIRMENT - (03/06/19)   CABOTEGRAVIR IS NOT ASSOCIATED WITH WEIGHT GAIN IN HIV-NEGATIVE INDIVIDUALS - (03/06/19)   Evaluation of Neural Tube Defects After Exposure to Raltegravir During Pregnancy - (03/06/19)   BREAKING BONES IS BAD: INCIDENT FRACTURE AND MORTALITY IN THE HIV OUTPATIENT STUDY - 45% Increased Mortality Associated with Fracture - (03/06/19)   Antiactivation activity with kinase inhibitor - JAK Inhbitor - added to suppressive ART / "Safety, tolerability and immunologic activity of ruxolitinib added to suppressive ART" - Mark Mascolini (03/05/19)   Longer sustained use of levonorgestrel IUD than copper IUD by women with HIV / "Randomized controlled trial of intrauterine device safety in women living with HIV" - Mark Mascolini (03/05/19)   Better HIV control with dolutegravir than efavirenz started late in pregnancy / "RCT of dolutegravir vs efavirenz-based therapy initiated in late pregnancy: DOLPHIN-2" - Mark Mascolini (03/05/19)   COPD doubles heart attack risk with HIV regardless of smoking / "COPD and the risk of MI by type in people living with HIV" - Mark Mascolini (03/05/19)   Sudden cardiac death risk higher with HIV--but not with sustained HIV control / "Sudden cardiac death among HIV-infected and -uninfected veterans" - Mark Mascolini (03/05/19)   Probiotic does not alter inflammation/activation markers in group on stable ART / "Assessing the probiotic effect in treated HIV: results of ACTG A5350" - Mark Mascolini (03/05/19)   HIV tied to almost 2-fold lower breast cancer survival - Mark Mascolini (03/05/19)   Has a second person with HIV been cured? - (03/05/19)   UPDATE ON HIV PREVENTION CROI 2019 - (03/05/19)   UPDATE ON HIV CURE - CROI 2019 - (03/05/19)   NASH IN HIV - CROI 2019 - (03/05/19)   RETREATMENT OF HCV IN ADVANCED LIVER DISEASE / CROI 2019 - (03/05/19)